19th Ave New York, NY 95822, USA

Grupo de Oncología Molecular

El Grupo de Oncología Molecular del VHIO aplica tecnologías de vanguardia basadas en el análisis de tejidos en la investigación básica, traslacional y clínica, con el objetivo de desarrollar y validar nuevos biomarcadores tumorales para la oncología de precisión.

En colaboración con el Grupo de Genómica del Cáncer del VHIO, liderado por Ana Vivancos; el Grupo de Ciencia de Datos en Oncología – ODysSey, liderado por Rodrigo Dienstmann; y la Unidad de Investigación de Terapia Molecular del Cáncer (UITM) – CaixaResearch, dirigida por Elena Garralda, codirigimos el Programa de Precribado Molecular del VHIO, con el apoyo de la Fundación FERO. Cada año realizamos el perfil molecular de más de 1.100 pacientes potencialmente candidatos a participar en ensayos clínicos de fases iniciales en la UITM-CaixaResearch.

Nuestro grupo también actúa como una de las plataformas tecnológicas del VHIO, y nuestro laboratorio contribuye a las líneas y programas de investigación del Instituto. Nuestra actividad incluye análisis de biomarcadores para la estratificación de pacientes, patología digital, banco de tejidos y desarrollo de modelos de xenoinjertos derivados de pacientes (PDX). En 2024, nuestras contribuciones se reflejaron en múltiples publicaciones en coautoría en revistas de alto impacto.

Como grupo independiente, investigamos la relación entre el microbioma intestinal y el cáncer. Estas investigaciones han dado lugar a contribuciones importantes en este ámbito, como la demostración de la presencia de Fusobacterium nucleatum y de la microbiota asociada en las metástasis hepáticas del cáncer colorrectal (CCR) (Bullman et al., Science, 2017), así como el papel pronóstico de la persistencia de Fusobacterium tras la quimiorradioterapia neoadyuvante (nCRT) en cánceres de recto localmente avanzados (Serna et al., Ann Oncol, 2020). A partir de estos resultados, codirigimos el WP3 del proyecto OPTIMISTICC Cancer Grand Challenge, financiado por Cancer Research UK (CRUK). Con el apoyo de la Fundación Mutua Madrileña y del Instituto de Salud Carlos III (ISCIII), también lideramos el proyecto FUSOMAP, destinado a desarrollar modelos diagnósticos y pronósticos basados en la microbiota para el CCR en estadios iniciales.

Como plataforma científica (Core Facility), hemos dado apoyo a más de 400 estudios clínicos realizados en el Hospital Vall d’Hebron, contribuyendo al 70 % de todos los ensayos en curso en nuestro Instituto. Nuestra participación incluye la coordinación de la recogida, el almacenamiento y el envío de muestras; el desarrollo y la realización de ensayos en «tiempo real» para orientar la inclusión de pacientes en estos estudios; y la realización de estudios de monitorización farmacodinámica y de determinación de dosis.

En 2024 realizamos más de 3.500 ensayos moleculares en muestras destinadas a la inclusión en ensayos clínicos y más de 20.000 pruebas para dar apoyo a la investigación básica y traslacional. También actuamos como laboratorio central de referencia para varios estudios internacionales y mantuvimos con éxito nuestra acreditación ISO 15189, garantizando así la continuidad de la excelencia en calidad y competencia.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Figura: Flujo de trabajo para la generación automatizada de máscaras de segmentación tumoral e inmunitaria a partir de Pan-queratina (PanCK) y CD3, realizada en el mismo portaobjetos mediante NGI (Next-Generation Immunohistochemistry), una técnica de inmunohistoquímica secuencial. Tras la alineación con la tinción H&E obtenida del mismo portaobjetos, las segmentaciones resultantes se utilizan para entrenar un modelo de inteligencia artificial capaz de predecir directamente la segmentación sobre H&E. Serna G, et al., European Congress on Digital Pathology (ECDP), P15, 2025.

Paolo G. Nuciforo
Jefe de grupo

Como centro de referencia:

  • Aplicar estrategias de patología molecular para apoyar el desarrollo clínico temprano de fármacos.
  • Definir la epidemiología de los objetivos terapéuticos para ayudar a desarrollar estrategias de tratamiento personalizadas en oncología.
  • Actuar como laboratorio académico central y local en ensayos clínicos y como plataforma tecnológica de referencia para la patología clínica y experimental en el VHIO.

Como grupo independiente:

  • Ampliar los conocimientos sobre el microbioma del cáncer mediante el análisis de la microbiota asociada al cáncer para identificar biomarcadores diagnósticos, pronósticos y/o predictivos en el cáncer colorrectal y otros tipos de tumores.
  • Desarrollar metodologías novedosas para mejorar la cuantificación y la reproducibilidad de los biomarcadores en el cáncer, centrándonos en los cánceres de mama y colorrectal.
  • Investigar el valor del análisis de la «contextura inmunitaria» del microambiente tumoral como biomarcador de la respuesta a la inmunoterapia en diferentes tipos de cáncer.
  • Explorar la utilidad de la inteligencia artificial (IA) en patología y oncología de precisión mediante el desarrollo de enfoques multimodales que utilicen preparaciones teñidas con H&E e IHC para la cuantificación reproducible y supervisada semanalmente de biomarcadores, así como para el reconocimiento de patrones de imagen clínicamente relevantes.
Jefe de grupo
Paolo G. Nuciforo
Médicos adjuntos
Roberta Fasani
Siarhei Mauchanski
Artur Mezheyeuski
Sara Simonetti
Supervisor de laboratorio
Jose Antonio Jiménez
Asistente de laboratorio
Laura Boleda
Mª Ángeles Diaz
Joel Luque
Investigadores Posdoctorales
Monica Aguilera
Francisca Gallego
Stefania Napoli
Alba Santiago
Garazi Serna
Estudiantes Doctorales
Diego Alfonso Arregui
Técnicos
Lidia Alonso
Nuria Aybar
Luis Garcia
Margarita González
Xavier Guardia
Paula León
Anaïs Mallén
Paola Martinez
Júlia Reig
Gertrudis Sánchez
Lidia Sánchez
César Sevillano

Publicaciones científicas más relevantes

  • Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas AB, Keough K, Galvao V, Alonso G, Olano AM, Vieito Villar M, Oberoi A, Lostes Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro FCP, Li B, Pyke RM, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen RO, Boyle SM, Toledo RA. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clin Cancer Res. 2025. doi: 10.1158/1078-0432.CCR-25-2312.
  • Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO Open. 2025 Nov;10(11):105888.
  • Karta J, Meyers M, Rodriguez F, Koncina E, Gilson C, Klein E, Gabola M, Benzarti M, Pérez Escriva P, Molina Tijeras JA, Correia Tavares Bernardino C, Ponath F, Carpentier A, Pujabet MA, Schmoetten M, Tsenkova M, Saoud P, Gaigneaux A, Ternes D, Alonso L, Zügel N, Willemssen E, Koppes P, Léonard D, Casanova LP, Haan S, Mittelbronn M, Meiser J, Pozdeev VI, Vogel J, Nuciforo PG, Wilmes P, Letellier E. Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer. EMBO J. 2025 Oct;44(19):5375-5393.
  • Moreno-Cárdenas AB, Ros J, Gil-Vila A, Datta D, Fasani R, Serna G, Jimenez J, Trallero-Araguás E, Viaplana C, Lostes J, Milisenda JC, Grau-Junyent JM, Lopez-Perez R, Pinal-Fernández I, Nuciforo P, Toledo RA, Selva-O’Callaghan A. Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. Ann Rheum Dis. 2025 Nov 24:S0003-4967(25)04457-7.
  • Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 Mar;181:92-101.
  • Cedres S, Serna G, Gonzalez-Medina A, Valdivia A, Assaf-Pastrana JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Priano I, Fasani R, Guardia X, Gonzalo J, Carbonell C, Frigola J, Amat R, Navarro V, Dienstmann R, Vivancos A, Nuciforo P, Felip E. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients. Cancers (Basel). 2023 Jul 14;15(14):3611.
  • Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5.
  • Saura C, Ortiz C, Matito J, Arenas EJ, Suñol A, Martín Á, Córdoba O, Martínez-Sabadell A, García-Ruiz I, Miranda I, Morales-Comas C, Carrasco E, Viaplana C, Peg V, Nuciforo P, Bayó-Puxan N, Gonzalez-Medina A, Miquel JM, Gómez-Rey M, Villacampa G, Arévalo S, Espinosa-Bravo M, Balmaña J, Dienstmann R, Arribas J, Tabernero J, Vivancos A, Sansó M. Early-Stage Breast Cancer Detection in Breast Milk. Cancer Discov. 2023 Oct 5;13(10):2180-2191.
  • Cedres S, Serna G, Gonzalez-Medina A, Valdivia A, Assaf-Pastrana JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Priano I, Fasani R, Guardia X, Gonzalo J, Carbonell C, Frigola J, Amat R, Navarro V, Dienstmann R, Vivancos A, Nuciforo P, Felip E. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients. Cancers (Basel). 2023 Jul 14;15(14):3611.
  • Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5.
  • Saura C, Ortiz C, Matito J, Arenas EJ, Suñol A, Martín Á, Córdoba O, Martínez-Sabadell A, García-Ruiz I, Miranda I, Morales-Comas C, Carrasco E, Viaplana C, Peg V, Nuciforo P, Bayó-Puxan N, Gonzalez-Medina A, Miquel JM, Gómez-Rey M, Villacampa G, Arévalo S, Espinosa-Bravo M, Balmaña J, Dienstmann R, Arribas J, Tabernero J, Vivancos A, Sansó M. Early-Stage Breast Cancer Detection in Breast Milk. Cancer Discov. 2023 Oct 5;13(10):2180-2191.
  • Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 Mar;181:92-101. Epub 2022 Dec 27.
  • Borgognone A, Serna G, Noguera-Julian M, Alonso L, Parera M, Català-Moll F, Sanchez L, Fasani R, Paredes R, Nuciforo P. Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Cancers (Basel). 2021 Oct 29;13(21):5421.
  • Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23.
  • Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci. 2021 Feb 1;22(3):1446.
  • Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. J Clin Invest. 2021 Mar 15;131(6):e145427.
  • Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P.NPJ Precis Oncol. 2021 Mar 19;5(1):23. doi: 10.1038/s41698-021-00163-6.
  • Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P.J Clin Invest. 2021 Mar 15;131(6):e145427. doi: 10.1172/JCI145427.
  • Serna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, Comas R, Jimenez J, Elez E, Bullman S, Tabernero J, Capdevila J, Dienstmann R, Nuciforo P. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366-1375.
  • Serna G, Simonetti S, Fasani R, Pagliuca F, Guardia X, Gallego P, Jimenez J, Peg V, Saura C, Eppenberger-Castori S, Ramon Y Cajal S, Terracciano L, Nuciforo P. Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. Breast. 2020 Oct;53:102-110.
  • Dienstmann R, Garralda E, Aguilar S, Sala G, Viaplana C, Ruiz-Pace F, González- Zorelle J, Grazia LoGiacco D, Ogbah Z, Ramos Masdeu L, Mancuso F, Fasani R, Jimenez J, Martinez P, Oaknin A, Saura C, Oliveira M, Balmaña J, Carles J, Macarulla T, Elez E, Alsina M, Braña I, Felip E, Tabernero J, Rodon J, Nuciforo P, Vivancos A. Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precis Oncol. 2020 May 14;4:PO.19.00398.
  • Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol. 2019 Nov 1;30(11):1843.
  • Vivancos A, Élez E, Salazar R. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime? Ann Oncol.29: 532-534.
  • Capdevila J,Mayor R; Mancuso FF, Iglesias C; Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol.29: 1454-1460.
  • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P,Mancuso F, Serra V, Vivancos A. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst.110: 914-917.
  • Puig I, Tenbaum SP, Chicote I, Arqués O,Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P,Seoane J,Recio JA, Vivancos A,Dienstmann R,Tabernero J,Palmer HG.TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest.128: 3887-3905.
  • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S,Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN; Kristel P, de Bustos L, Guzman M,Rodriguez O, Grueso J, Montalban G, Caratú G,Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O; O’Connor MJ, Balmaña J,Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol.29: 1203-1210. IF: 13,926
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, Lopez-Bigas N, Ramón Y Cajal S, Vieito M, Carles J, Tabernero J,Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid.Clin Cancer Res.24: 2812-2819.

Todas las publicaciones

  • Garralda E, Abbott C, Calahorro A, Mirallas O, Pugh J, Moreno-Cárdenas AB, Keough K, Galvao V, Alonso G, Olano AM, Vieito Villar M, Oberoi A, Lostes Bardaji J, Hernando-Calvo A, Braña I, Pretelli G, Ortega B, Arenillas C, Czerniak N, Navarro FCP, Li B, Pyke RM, Ravi N, Zatse C, Grussu F, Sanz M, Viaplana C, Raskina K, Jimenez J, Fasani R, Casbas-Hernandez P, Oflazoglu E, Hodgson D, Reis-Filho J, Felip E, Élez E, Muñoz E, Dienstmann R, Tabernero J, Lopez-Perez R, Nuciforo P, Chen RO, Boyle SM, Toledo RA. Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy. Clin Cancer Res. 2026 Jan 16;32(2):333-349. doi: 10.1158/1078-0432.CCR-25-2312. PubMed PMID: 41400436; PubMed Central PMCID: PMC12809116.
  • Navarro-Garcia D, Grussu F, Zatse C, Klümper N, Macarro C, Hernando-Calvo A, Sanz M, Vieito M, Braña I, Mirallas O, Alonso G, Galvao V, Pretelli G, Lostes J, Oberoi A, Toledo R, Nuciforo P, Garralda E, Perez-Lopez R. Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy response. J Immunother Cancer. 2025 Dec 21;13(12). doi: 10.1136/jitc-2025-012143. PubMed PMID: 41423273; PubMed Central PMCID: PMC12718596.
  • Grigoriou A, Macarro C, Palombo M, Navarro-Garcia D, Voronova AK, Bernatowicz K, Barba I, Escriche A, Greco E, Abad M, Simonetti S, Serna G, Mast R, Merino X, Roson N, Escobar M, Vieito M, Nuciforo P, Toledo R, Garralda E, Sala-Llonch R, Fieremans E, Novikov DS, Perez-Lopez R, Grussu F. Histology-informed microstructural diffusion simulations for MRI cancer characterisation-the Histo-μSim framework. Commun Biol. 2025 Nov 26;8(1):1695. doi: 10.1038/s42003-025-09096-3. PubMed PMID: 41298809; PubMed Central PMCID: PMC12657972.
  • Moreno-Cárdenas AB, Ros J, Gil-Vila A, Datta D, Fasani R, Serna G, Jimenez J, Trallero-Araguás E, Viaplana C, Lostes J, Milisenda JC, Grau-Junyent JM, Lopez-Perez R, Pinal-Fernández I, Nuciforo P, Toledo RA, Selva-O’Callaghan A. Frequent genetic alterations in myositis autoantigen genes in cancer-associated dermatomyositis. Ann Rheum Dis. 2025 Nov 24;. doi: 10.1016/j.ard.2025.10.018. [Epub ahead of print] PubMed PMID: 41290487.
  • Grussu F, Grigoriou A, Bernatowicz K, Palombo M, Casanova-Salas I, Navarro-Garcia D, Barba I, Simonetti S, Serna G, Macarro C, Voronova AK, Garay V, Corral JF, Vidorreta M, García-Polo García P, Merino X, Mast R, Rosón N, Escobar M, Vieito M, Toledo R, Nuciforo P, Mateo J, Garralda E, Perez-Lopez R. Clinically feasible liver tumour cell size measurement through histology-informed in vivo diffusion MRI. Commun Med (Lond). 2025 Nov 20;5(1):535. doi: 10.1038/s43856-025-01246-2. PubMed PMID: 41266804; PubMed Central PMCID: PMC12749696.
  • Rondon-Lorefice I, Lopez JI, Ugalde-Olano A, Zufiaurre M, Astobiza I, Martin-Martin N, Bozal-Basterra L, Garcia-Longarte S, Zabala-Letona A, Rey S, Santos-Martin A, Unda M, Loizaga-Iriarte A, Graupera M, Nuciforo P, Carracedo A, Mendizabal I. Transcriptional network analysis of PTEN-protein-deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication. Mol Oncol. 2025 Nov 17;. doi: 10.1002/1878-0261.70164. [Epub ahead of print] PubMed PMID: 41247227.
  • Dienstmann R, Vivancos A, Nuciforo P, Aguilar S, Ruiz-Pace F, Viaplana C, Gonzalez J, Fite B, Pedrola A, Elez E, Saura C, Felip E, Macarulla T, Capdevila J, Fariñas-Madrid L, Carles J, Mateo J, Muñoz-Cosuelo E, Balmaña J, Braña I, Garralda E, Tabernero J. Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors. ESMO Open. 2025 Nov;10(11):105888. doi: 10.1016/j.esmoop.2025.105888. Epub 2025 Nov 6. PubMed PMID: 41202500; PubMed Central PMCID: PMC12639418.
  • Catani G, Morchón-Araujo D, Mirallas O, Sánchez-Pérez V, Nuciforo P, Villacampa G, Dienstmann R, Vivancos A, Garralda E, Hernando-Calvo A. Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies. Front Immunol. 2025;16:1664443. doi: 10.3389/fimmu.2025.1664443. eCollection 2025. Review. PubMed PMID: 41200168; PubMed Central PMCID: PMC12586187.
  • Pascual T, Villacampa G, Oliveira M, Escrivá-de-Romaní S, Pernas S, Paré L, Adamo B, Martínez E, Cortés J, Perelló A, Galan M, Melé M, Villanueva L, Gonzalez-Rodriguez M, Tolosa P, González-Farré B, Galván P, Canes J, Nuciforo P, Ferrero-Cafiero JM, González-Farré X, Villagrasa P, Prat A, Ciruelos E. Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial. ESMO Open. 2025 Sep;10(9):105572. doi: 10.1016/j.esmoop.2025.105572. Epub 2025 Sep 1. PubMed PMID: 40896880; PubMed Central PMCID: PMC12424417.
  • Karta J, Meyers M, Rodriguez F, Koncina E, Gilson C, Klein E, Gabola M, Benzarti M, Pérez Escriva P, Molina Tijeras JA, Correia Tavares Bernardino C, Ponath F, Carpentier A, Pujabet MA, Schmoetten M, Tsenkova M, Saoud P, Gaigneaux A, Ternes D, Alonso L, Zügel N, Willemssen E, Koppes P, Léonard D, Casanova LP, Haan S, Mittelbronn M, Meiser J, Pozdeev VI, Vogel J, Nuciforo PG, Wilmes P, Letellier E. Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer. EMBO J. 2025 Oct;44(19):5375-5393. doi: 10.1038/s44318-025-00542-w. Epub 2025 Aug 22. PubMed PMID: 40846900; PubMed Central PMCID: PMC12488894.
  • Castet F, Salcedo MT, Nuciforo P, Aguilar S, Vivancos A. Best practices in sample management and molecular profiling of cholangiocarcinoma: a practical guide. Expert Rev Mol Diagn. 2025 Aug;25(8):479-494. doi: 10.1080/14737159.2025.2518145. Epub 2025 Jun 12. Review. PubMed PMID: 40497693.
  • Pedretti F, Abdalfttah M, Pellegrino B, Mateo F, Martínez-Sanz P, Herencia-Ropero A, Òdena A, Clavell-Revelles P, Casali G, Domènech H, Monserrat L, Papić D, Mas Malavila A, Pascual-Reguant A, Eixarch H, Guzmán M, Rodríguez O, Grueso J, Simonetti S, Fasani R, Nuciforo P, Espejo C, Florian S, Pujana MÁ, Nonell L, Seoane J, Valge-Archer V, O’Connor MJ, Nieto JC, Heyn H, Balmaña J, Llop-Guevara A, Serra V. Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer. Cancer Res. 2025 May 15;85(10):1888-1908. doi: 10.1158/0008-5472.CAN-24-2531. PubMed PMID: 40067927.
  • Arenillas C, Celada L, Ruiz-Cantador J, Calsina B, Datta D, García-Galea E, Fasani R, Moreno-Cárdenas AB, Alba-Linares JJ, Miranda-Barrio B, Martínez-Montes ÁM, Alvarez-Escola C, Lecumberri B, González García A, K Flores S, Esquivel E, Ding Y, Peitzsch M, Robles-Guirado JÁ, Regojo Zapata RM, Pozo-Kreilinger JJ, Iglesias C, Dwight T, Muir CA, Oleaga A, Garrido-Lestache Rodríguez-Monte ME, Del Cerro MJ, Martínez-Bendayán I, Álvarez-González E, Cubiella T, Lourenço DM Jr, A Pereira MA, Burnichon N, Buffet A, Broberg C, Dickson PV, Fraga MF, Llorente Pendás JL, Rueda Soriano J, Buendía Fuentes F, Toledo SPA, Clifton-Bligh R, Dienstmann R, Villanueva J, Capdevila J, Gimenez-Roqueplo AP, Favier J, Nuciforo P, Young WF Jr, Bechmann N, Opotowsky AR, Vaidya A, Bancos I, Weghorn D, Robledo M, Casteràs A, Dos-Subirà L, Adameyko I, Chiara MD, Dahia PLM, Toledo RA. Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes. Cancer Discov. 2025 May 2;15(5):1037-1062. doi: 10.1158/2159-8290.CD-24-0943. PubMed PMID: 40199338; PubMed Central PMCID: PMC12046333.
  • El-Khoueiry A, Saavedra O, Thomas J, Livings C, Garralda E, Hintzen G, Kohlhas L, Vanosmael D, Koch J, Rajkovic E, Ravenstijn P, Nuciforo P, Fehniger TA, Foster M, Berrien-Elliott MM, Wingert S, Stäble S, Morales-Espinosa D, Rivas D, Emig M, Lopez J. First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors. Clin Cancer Res. 2025 Apr 1;31(7):1257-1267. doi: 10.1158/1078-0432.CCR-24-1991. PubMed PMID: 39846810; PubMed Central PMCID: PMC11964176.
  • Voronova AK, Grigoriou A, Bernatowicz K, Simonetti S, Serna G, Roson N, Escobar M, Vieito M, Nuciforo P, Toledo R, Garralda E, Fieremans E, Novikov DS, Palombo M, Perez-Lopez R, Grussu F. SpinFlowSim: A blood flow simulation framework for histology-informed diffusion MRI microvasculature mapping in cancer. Med Image Anal. 2025 May;102:103531. doi: 10.1016/j.media.2025.103531. Epub 2025 Mar 7. PubMed PMID: 40073583; PubMed Central PMCID: PMC12034030.
  • Arce-Gallego S, Cresta Morgado P, Delgado-Serrano L, Simonetti S, Gonzalez M, Romero-Lozano P, Marmolejo D, Morales-Barrera R, Arnau GM, Semidey ME, Aguilar D, Cordoba-Terreros S, Mast R, de Albert M, Planas J, Cuadras M, Maldonado X, Suarez C, Casanova-Salas I, Figols M, Cros S, Mas A, Nonell L, Dienstmann R, Nuciforo P, Vivancos A, Llop-Guevara A, Carles J, Serra V, Mateo J. Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. Cell Rep Med. 2025 Feb 18;6(2):101937. doi: 10.1016/j.xcrm.2025.101937. Epub 2025 Feb 5. PubMed PMID: 39914385; PubMed Central PMCID: PMC11866514.
  • Bernatowicz K, Amat R, Prior O, Frigola J, Ligero M, Grussu F, Zatse C, Serna G, Nuciforo P, Toledo R, Escobar M, Garralda E, Felip E, Perez-Lopez R. Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction. J Immunother Cancer. 2025 Jan 11;13(1). doi: 10.1136/jitc-2024-009140. PubMed PMID: 39800381; PubMed Central PMCID: PMC11749429.
  • Saura C, Ortiz C, Matito J, Arenas EJ, Suñol A, Martín Á, Córdoba O, Martínez-Sabadell A, García-Ruiz I, Miranda I, Morales-Comas C, Carrasco E, Viaplana C, Peg V, Nuciforo P, Bayó-Puxan N, Gonzalez-Medina A, Miquel JM, Gómez-Rey M, Villacampa G, Arévalo S, Espinosa-Bravo M, Balmaña J, Dienstmann R, Arribas J, Tabernero J, Vivancos A, Sansó M. Early-Stage Breast Cancer Detection in Breast Milk. Cancer Discov. 2023 Oct 5;13(10):2180-2191.
  • Mosconi P, Colombo C, Paletta P, Gangeri L, Pellegrini C, Garralda E, Miceli R, Brunelli C; CEE_DART Consortium. Public and patient involvement: a survey on knowledge, experience and opinions among researchers within a precision oncology European project. BMC Cancer. 2023 Aug 30;23(1):814.
  • Hernando-Calvo A, Vila-Casadesús M, Bareche Y, Gonzalez-Medina A, Abbas-Aghababazadeh F, Lo Giacco D, Martin A, Saavedra O, Brana I, Vieito M, Fasani R, Stagg J, Mancuso F, Haibe-Kains B, Han M, Berche R, Pugh TJ, Mirallas O, Jimenez J, Gonzalez NS, Valverde C, Muñoz-Couselo E, Suarez C, Diez M, Élez E, Capdevila J, Oaknin A, Saura C, Macarulla T, Galceran JC, Felip E, Dienstmann R, Bedard PL, Nuciforo P, Seoane J, Tabernero J, Garralda E, Vivancos A. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med. 2023 Oct 13;4(10):710-727.e5.
  • Cuesta-Borràs E, Salvans C, Arqués O, Chicote I, Ramírez L, Cabellos L, Martínez-Quintanilla J, Mur-Espinosa A, García-Álvarez A, Hernando J, Tejedor JR, Mirallas O, Élez E, Fraga MF, Tabernero J, Nuciforo P, Capdevila J, Palmer HG, Puig I. DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype. Cell Rep. 2023 Aug 29;42(8):112927.
  • Cedres S, Serna G, Gonzalez-Medina A, Valdivia A, Assaf-Pastrana JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Priano I, Fasani R, Guardia X, Gonzalo J, Carbonell C, Frigola J, Amat R, Navarro V, Dienstmann R, Vivancos A, Nuciforo P, Felip E. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients. Cancers (Basel). 2023 Jul 14;15(14):3611.
  • Pujals M, Mayans C, Bellio C, Méndez O, Greco E, Fasani R, Alemany-Chavarria M, Zamora E, Padilla L, Mitjans F, Nuciforo P, Canals F, Nonell L, Abad M, Saura C, Tabernero J, Villanueva J. RAGE/SNAIL1 signaling drives epithelial-mesenchymal plasticity in metastatic triple-negative breast cancer. Oncogene. 2023 Aug;42(35):2610-2628.
  • Capdevila J, Hernando J, Teule A, Lopez C, Garcia-Carbonero R, Benavent M, Custodio A, Garcia-Alvarez A, Cubillo A, Alonso V, Carmona-Bayonas A, Alonso-Gordoa T, Crespo G, Jimenez-Fonseca P, Blanco M, Viudez A, La Casta A, Sevilla I, Segura A, Llanos M, Landolfi S, Nuciforo P, Manzano JL. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun. 2023 May 23;14(1):2973.
  • Baraibar I, García A, Salvà F, Ros J, Saoudi N, Comas R, Castillo G, Sanchis M, García-Álvarez A, Hernando J, Capdevila J, Castells MR, Martí M, Landolfi S, Espín E, Navalpotro B, Guevara J, Dopazo C, Nuciforo P, Vivancos A, Tabernero J, Élez E. Impact of the COVID-19 pandemic in the early-onset colorectal cancer. Transl Oncol. 2023 Jun;32:101668.
  • Di Cosimo S, Ciniselli CM, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez HL, Iorio MV, Vingiani A, Pruneri G, Verderio P. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front Oncol. 2023 Jan 31;12:1028825.
  • Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer. Eur J Cancer. 2023 Mar;181:92-101
  • Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart M, Di Cosimo S, de Azambuja E, Demeestere I. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer. J Natl Compr Canc Netw. 2023 Jan;21(1):33-41.e16.
  • Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, Llombart-Cussac A, Prat A, Perou CM, Carey LA. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. JAMA Oncol. 2023 Apr 1;9(4):490-499.
  • Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernadó-Morales C, Haro N, Giles FJ, Pozo ÓJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV. Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation. Clin Cancer Res. 2023 Jan 17;29(2):432-445.
  • Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci. 2021 Feb 1;22(3):1446.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nat Commun. 2021 Mar 8;12(1):1503.
  • Cribiù FM, Erra R, Pugni L, Rubio-Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Piñana M, Matter M, Tzankov A, Terracciano L, Anton A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J, Nuciforo P. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. J Clin Invest. 2021 Mar 15;131(6):e145427.
  • Griguolo G, Serna G, Pascual T, Fasani R, Guardia X, Chic N, Paré L, Pernas S, Muñoz M, Oliveira M, Vidal M, Llombart-Cussac A, Cortés J, Galván P, Bermejo B, Martínez N, López R, Morales S, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Prat A, Nuciforo P. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer. NPJ Precis Oncol. 2021 Mar 19;5(1):23.
  • Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2021 Mar 31:djab057.
  • Gris-Oliver A, Ibrahim YH, Rivas MA, García-García C, Sánchez-Guixé M, Ruiz-Pace F, Viaplana C, Pérez-García JM, Llombart-Cussac A, Grueso J, Parés M, Guzmán M, Rodríguez O, Anton P, Cozar P, Calvo MT, Bruna A, Arribas J, Caldas C, Dienstmann R, Nuciforo P, Oliveira M, Cortés J, Serra V. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. Br J Cancer. 2021 Apr;124(9):1581-1591.
  • Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. Mol Oncol. 2021 Apr;15(4):887-900.
  • Ligero M, Garcia-Ruiz A, Viaplana C, Villacampa G, Raciti MV, Landa J, Matos I, Martin-Liberal J, Ochoa-de-Olza M, Hierro C, Mateo J, Gonzalez M, Morales-Barrera R, Suarez C, Rodon J, Elez E, Braña I, Muñoz-Couselo E, Oaknin A, Fasani R, Nuciforo P, Gil D, Rubio-Perez C, Seoane J, Felip E, Escobar M, Tabernero J, Carles J, Dienstmann R, Garralda E, Perez-Lopez R. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 Apr;299(1):109-119.
  • De Mattos-Arruda L, Cortes J, Blanco-Heredia J, Tiezzi DG, Villacampa G, Gonçalves-Ribeiro S, Paré L, Souza CA, Ortega V, Sammut SJ, Cusco P, Fasani R, Chin SF, Perez-Garcia J, Dienstmann R, Nuciforo P, Villagrasa P, Rubio IT, Prat A, Caldas C. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. NPJ Breast Cancer. 2021 Jun 7;7(1):73
  • Ringborg U, Berns A, Celis JE, Heitor M, Tabernero J, Schüz J, Baumann M, Henrique R, Aapro M, Basu P, Beets-Tan R, Besse B, Cardoso F, Carneiro F, van den Eede G, Eggermont A, Fröhling S, Galbraith S, Garralda E, Hanahan D, Hofmarcher T, Jönsson B, Kallioniemi O, Kásler M, Kondorosi E, Korbel J, Lacombe D, Carlos Machado J, Martin-Moreno JM, Meunier F, Nagy P, Nuciforo P, Oberst S, Oliveiera J, Papatriantafyllou M, Ricciardi W, Roediger A, Ryll B, Schilsky R, Scocca G, Seruca R, Soares M, Steindorf K, Valentini V, Voest E, Weiderpass E, Wilking N, Wren A, Zitvogel L. The Porto European Cancer Research Summit 2021. Mol Oncol. 2021 Oct;15(10):2507-2543. doi: 10.1002/1878-0261.13078
  • Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, Sotiriou C. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. Clin Cancer Res. 2021 Oct 15;27(20):5607-5618.
  • Borgognone A, Serna G, Noguera-Julian M, Alonso L, Parera M, Català-Moll F, Sanchez L, Fasani R, Paredes R, Nuciforo P. Performance of 16S Metagenomic Profiling in Formalin-Fixed Paraffin-Embedded versus Fresh-Frozen Colorectal Cancer Tissues. Cancers (Basel). 2021 Oct 29;13(21):5421.
  • Martinez-Marti A, Felip E, Mancuso FM, Caratú G, Matito J, Nuciforo P, Sansano I, Diaz-Mejia N, Cedrés S, Callejo A, Iranzo P, Pardo N, Miquel JM, Navarro A, Vivancos A, Sansó M. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. Br J Cancer. 2021 Nov;125(11):1561-1569. doi: 10.1038/s41416-021-01558-9.
  • Wurm M, Schaaf O, Reutner K, Ganesan R, Mostböck S, Pelster C, Böttcher J, de Andrade Pereira B, Taubert C, Alt I, Serna G, Auguste A, Stadermann KB, Delic D, Han F, Capdevila J, Nuciforo PG, Kroe-Barrett R, Adam PJ, Vogt AB, Hofmann I. A Novel Antagonistic CD73 Antibody for Inhibition of the Immunosuppressive Adenosine Pathway. Mol Cancer Ther. 2021 Nov;20(11):2250-2261.
  • Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Nuciforo P, Canes J, Paré L, Dueñas M, Vidal M, Cejalvo JM, Perelló A, Llommbard-Cussac A, Dorca J, Montaño A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 2021 Nov 4;11:744112.
  • Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, Rimm DL. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer. Clin Cancer Res. 2021 Nov 15;27(22):6156-6163.
  • Pascual T, Oliveira M, Villagrasa P, Ortega V, Paré L, Bermejo B, Morales S, Amillano K, López R, Galván P, Canes J, Salvador F, Nuciforo P, Rubio IT, Llombart-Cussac A, Di Cosimo S, Baselga J, Harbeck N, Prat A, Cortés J. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. NPJ Breast Cancer. 2021 Nov 25;7(1):145.
  • Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. Clin Cancer Res. 2021 Dec 1;27(23):6307-6313.
  • El Bairi K, Haynes HR, Blackley E, Fineberg S, Shear J, Turner S, de Freitas JR, Sur D, Amendola LC, Gharib M, Kallala A, Arun I, Azmoudeh-Ardalan F, Fujimoto L, Sua LF, Liu SW, Lien HC, Kirtani P, Balancin M, El Attar H, Guleria P, Yang W, Shash E, Chen IC, Bautista V, Do Prado Moura JF, Rapoport BL, Castaneda C, Spengler E, Acosta-Haab G, Frahm I, Sanchez J, Castillo M, Bouchmaa N, Md Zin RR, Shui R, Onyuma T, Yang W, Husain Z, Willard-Gallo K, Coosemans A, Perez EA, Provenzano E, Ericsson PG, Richardet E, Mehrotra R, Sarancone S, Ehinger A, Rimm DL, Bartlett JMS, Viale G, Denkert C, Hida AI, Sotiriou C, Loibl S, Hewitt SM, Badve S, Symmans WF, Kim RS, Pruneri G, Goel S, Francis PA, Inurrigarro G, Yamaguchi R, Garcia-Rivello H, Horlings H, Afqir S, Salgado R, Adams S, Kok M, Dieci MV, Michiels S, Demaria S, Loi S; International Immuno-Oncology Biomarker Working Group. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021 Dec 1;7(1):150.
  • Shi Z, Wulfkuhle J, Nowicka M, Gallagher RI, Saura C, Nuciforo PG, Calvo I, Andersen J, Passos-Coelho JL, Gil-Gil MJ, Bermejo B, Pratt DA, Ciruelos EM, Villagrasa P, Wongchenko MJ, Petricoin EF, Oliveira M, Isakoff SJ. Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer. Clin Cancer Res. 2021 Dec 14. doi: 10.1158/1078-0432.CCR-21-2498. Epub ahead of print. PMID: 34907082.
  • Senís E, Esgleas M, Najas S, Jiménez-Sábado V, Bertani C, Giménez-Alejandre M, Escriche A, Ruiz-Orera J, Hergueta-Redondo M, Jiménez M, Giralt A, Nuciforo P, Albà MM, Peinado H, Del Toro D, Hove-Madsen L, Götz M, Abad M. TUNAR lncRNA Encodes a Microprotein that Regulates Neural Differentiation and Neurite Formation by Modulating Calcium Dynamics. Front Cell Dev Biol. 2021 Dec 31;9:747667.
  • Chic, Nuria ; Luen, Stephen J ; NUCIFORO, PAOLO GIOVANNI; Salgado, Roberto ; Fumagalli, Debora ; Hilbers, Florentine ; Wang, Yingbo ; de Azambuja, Evandro ; Làng, István ; DI COSIMO, SERENA; SAURA MANICH, CRISTINA; Huober, Jens ; PRAT APARICIO, ALEIX; Loi, Sherene. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.1093/jnci/djab057
  • Frigola, Joan; NAVARRO MENDIVIL, ALEJANDRO; Carbonell, Caterina ; Callejo, Ana ; Iranzo, Patricia ; CEDRES PEREZ, SUSANA; MARTINEZ MARTI, ALEXANDRE; PARDO ARANDA, NURIA; Saoudi-Gonzalez, Nadia ; Martinez, Debora ; JIMENEZ, JOSE; Sansano, Irene ; MANCUSO, FRANCESCO MATTIA; NUCIFORO, PAOLO GIOVANNI; Montuenga, Luis M ; Sánchez-Cespedes, Montse ; PRAT APARICIO, ALEIX; VIVANCOS PRELLEZO, ANA; FELIP FONT, ENRIQUETA; AMAT FERRER, RAMON. Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer. MOLECULAR ONCOLOGY. 2021 April. 10.1002/1878-0261.12891
  • LIGERO HERNANDEZ, MARTA; Garcia-Ruiz, Alonso ; VIAPLANA DONATO, CRISTINA; VILLACAMPA JAVIERRE, GUILLERMO; Raciti, Maria V ; Landa, Jaid ; MATOS GARCIA, IGNACIO; MARTIN LIBERAL, JUAN JESUS; OCHOA DE OLZA AMAT, MARIA; HIERRO CARBO, CINTA; MATEO VALDERRAMA, JOAQUIN; Gonzalez, Macarena ; MORALES BARRERA, RAFAEL; SUAREZ RODRIGUEZ, CRISTINA; RODON AHNERT, JORDI; ELEZ FERNANDEZ, MARIA ELENA; BRAÑA GARCIA, IRENE; MUÑOZ COUSELO, EVA; OAKNIN BENZAQUEN, ANA MAZALTOB; FASANI, ROBERTA; NUCIFORO, PAOLO GIOVANNI; Gil, Debora ; RUBIO, ISABEL TERESA; SEOANE SUAREZ, JOAN; FELIP FONT, ENRIQUETA; Escobar, Manuel ; TABERNERO CATURLA, JOSEP; CARLES GALCERAN, JOAN; DIENSTMANN, RODRIGO; GARRALDA CABANAS, ELENA; PEREZ LOPEZ, RAQUEL. A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Radiology. 2021 April. 10.1148/radiol.2021200928
  • RUBIO PEREZ, CARLOTA; Planas-Rigol, Ester ; Trincado, Juan L ; BONFILL TEIXIDOR, ESTER; ARIAS PIÑEIRO, ALEXANDRA; Marchese, Domenica ; Moutinho, Catia ; SERNA ALONSO, GARAZI; Pedrosa, Leire ; IURLARO, RAFFAELLA; Martínez-Ricarte, Francisco ; ESCUDERO MONREAL, LAURA; Cordero, Esteban ; Cicuendez, Marta ; Ruiz, Sara ; Parra, Genís ; NUCIFORO, PAOLO GIOVANNI; Gonzalez, Josep ; Pineda, Estela ; Sahuquillo, Juan ; TABERNERO CATURLA, JOSEP; Heyn, Holger ; SEOANE SUAREZ, JOAN. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. NATURE COMMUNICATIONS. 2020 March. 10.1038/s41467-021-21789-x
  • Oliva, Marc ; MULET MARGALEF, NURIA; OCHOA DE OLZA AMAT, MARIA; Napoli, Stefania ; Mas, Joan ; Laquente, Berta ; Alemany, Laia ; Duell, Eric J ; NUCIFORO, PAOLO GIOVANNI; Moreno, Victor. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. Tumor-Associated Microbiome: Where Do We Stand?. 2021 February. 10.3390/ijms22031446
  • Hudecek, J. ; Voorwerk, L. ; van Seijen, M. ; Nederlof, I. ; de Maaker, M. ; van den Berg, J. ; van de Vijver, K.K. ; Sikorska, K. ; Adams, S. ; Demaria, S. ; Viale, G. ; Nielsen, T.O. ; Badve, S.S. ; Michiels, S. ; Symmans, W.F. ; Sotiriou, C. ; Rimm, D.L. ; Hewitt, S.M. ; Denkert, C. ; Loibl, S. ; Loi, S. ; Bartlett, J.M.S. ; Pruneri, G. ; Dillon, D.A. ; Cheang, M.C.U. ; Tutt, A. ; Hall, J.A. ; Kos, Z. ; Salgado, R. ; Kok, M. ; Horlings, H.M. ; Hyytiäinen, A. ; Hida, A.I. ; Thompson, A. ; Lefevre, A. ; Lazar, A.J. ; Gown, A. ; Lo, A. ; Sapino, A. ; Madabhushi, A. ; Moreira, A. ; Richardson, A. ; Vingiani, A. ; Beck, A.H. ; Bellizzi, A.M. ; Guerrero, A. ; Grigoriadis, A. ; Ehinger, A. ; Garrido-Castro, A. ; Vincent-Salomon, A. ; Laenkholm, A.-V. ; Sharma, A. ; Cimino-Mathews, A. ; Srinivasan, A. ; Acs, B. ; Singh, B. ; Calhoun, B. ; Haibe-Kans, B. ; Solomon, B. ; Thapa, B. ; Nelson, B.H. ; Gallas, B.D. ; Castaneda, C. ; Ballesteros-Merino, C. ; Criscitiello, C. ; Boeckx, C. ; Colpaert, C. ; Quinn, C. ; Chennubhotla, C.S. ; Swanton, C. ; Solinas, C. ; Hiley, C. ; Drubay, D. ; Bethmann, D. ; Moore, D.A. ; Larsimont, D. ; Sabanathan, D. ; Peeters, D. ; Zardavas, D. ; Höflmayer, D. ; Johnson, D.B. ; Thompson, E.A. ; Brogi, E. ; Perez, E. ; ElGabry, E.A. ; Stovgaard, E.S. ; Blackley, E.F. ; Roblin, E. ; Reisenbichler, E. ; Bellolio, E. ; Balslev, E. ; Chmielik, E. ; Gaire, F. ; Andre, F. ; Lu, F.-I. ; Azmoudeh-Ardalan, F. ; Rojo, F. ; Gruosso, T. ; Ciompi, F. ; Peale, F. ; Hirsch, F.R. ; Klauschen, F. ; Penault-Llorca, F. ; Acosta Haab, G. ; Farshid, G. ; van den Eynden, G. ; Curigliano, G. ; Floris, G. ; Broeckx, G. ; Gonzalez-Ericsson ; Koeppen, H. ; Haynes, H.R. ; McArthur, H. ; Joensuu, H. ; Olofsson, H. ; Lien, H.-C. ; Chen, I.-C. ; Cree, I. ; Frahm, I. ; Brcic, I. ; Chan, J. ; Ziai, J. ; Brock, J. ; Wesseling, J. ; Giltnane, J. ; Kerner, J.K. ; Thagaard, J. ; Braybrooke, J.P. ; van der Laak, J.A.W.M. ; Lemonnier, J. ; Zha, J. ; Ribeiro, J. ; Lennerz, J.K. ; Carter, J.M. ; Saltz, J. ; Hartman, J. ; Hainfellner, J. ; Quesne, J.L. ; Juco, J.W. ; Reis-Filho, J. ; Sanchez, J. ; Sparano, J. ; Cucherousset, J. ; Araya, J.C. ; Adam, J. ; Balko, J.M. ; Saeger, K. ; Siziopikou, K. ; Willard-Gallo, K. ; Weber, K. ; Pogue-Geile, K.L. ; Steele, K.E. ; Emancipator, K. ; AbdulJabbar, K. ; El Bairi, K. ; Blenman, K.R.M. ; Allison, K.H. ; Korski, K. ; Pusztai, L. ; Comerma, L. ; Buisseret, L. ; Cooper, L.A.D. ; Shi, L. ; Kooreman, L.F.S. ; Molinero, L. ; Estrada, M.V. ; Lacroix-Triki, M. ; Al Bakir, M. ; Sebastian, M.M. ; van de Vijver, M. ; Balancin, M.L. ; Dieci, M.V. ; Mathieu, M.-C. ; Rebelatto, M.C. ; Piccart, M. ; Hanna, M.G. ; Goetz, M.P. ; Preusser, M. ; Khojasteh, M. ; Sanders, M.E. ; Regan, M.M. ; Barnes, M. ; Christie, M. ; Misialek, M. ; Ignatiadis, M. ; van Bockstal, M. ; Castillo, M. ; Amgad, M. ; Harbeck, N. ; Tung, N. ; Laudus, N. ; Sirtaine, N. ; Burchardi, N. ; Ternes, N. ; Radosevic-Robin, N. ; Gluz, O. ; Grimm, O. ; NUCIFORO, PAOLO GIOVANNI; Jank, P. ; Gonzalez-Ericsson, P. ; Kirtani, P. ; Jelinic, P. ; Watson, P.H. ; Savas, P. ; Francis, P.A. ; Russell, P.A. ; Singh, R. ; Kim, R.S. ; Pierce, R.H. ; Hills, R. ; Leon-Ferre, R. ; de Wind, R. ; Shui, R. ; De Clercq, S. ; Leung, S. ; Tabbarah, S. ; Souza, S.C. ; O’Toole, S. ; Swain, S. ; Dudgeon, S. ; Willis, S. ; Ely, S. ; Kim, S.-R. ; Bedri, S. ; Irshad, S. ; Liu, S.-W. ; Goel, S. ; Hendry, S. ; Bianchi, S. ; Bragança, S. ; Paik, S. ; Wienert, S. ; Fox, S.B. ; Luen, S.J. ; Naber, S. ; Schnitt, S.J. ; Sua, L.F. ; Lakhani, S.R. ; Fineberg, S. ; Soler, T. ; Gevaert, T. ; D’Alfonso, T. ; John, T. ; Sugie, T. ; Kurkure, U. ; Bossuyt, V. ; Manem, V. ; Cámara, V.P. ; Tong, W. ; Chen, W. ; Yang, W. ; Tran, W.T. ; Wang, Y. ; Yuan, Y. ; Allory, Y. ; Husain, Z. ; Bago-Horvath, Z. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. NPJ breast cancer. 2020 January. 10.1038/s41523-020-0155-1
  • Chic, Nuria ; Luen, Stephen J ; NUCIFORO, PAOLO GIOVANNI; Salgado, Roberto ; Fumagalli, Debora ; Hilbers, Florentine ; Wang, Yingbo ; de Azambuja, Evandro ; Làng, István ; DI COSIMO, SERENA; SAURA MANICH, CRISTINA; Huober, Jens ; PRAT APARICIO, ALEIX; Loi, Sherene. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.  JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2020 January. 10.1093/jnci/djz042
  • CAPDEVILA CASTILLON, JAUME; MATOS GARCIA, IGNACIO; MANCUSO, FRANCESCO MATTIA; Iglesias, Carmela; NUCIFORO, PAOLO GIOVANNI; Zafon, Carles ; GARCIA PALMER, HECTOR; OGBAH, ZIGHEREDA; Muinos, Laura ; HERNANDO CUBERO, JORGE; Villacampa, Guillermo ; Peña, Carol E ; TABERNERO CATURLA, JOSEP; Brose, Marcia S ; Schlumberger, Martin ; VIVANCOS PRELLEZO, ANA. Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. MOLECULAR CANCER THERAPEUTICS. 2020 January. 10.1158/1535-7163.MCT-19-0211
  • Cebrià-Costa, J P ; PASCUAL REGUANT, LAURA; Gonzalez-Perez, A ; Serra-Bardenys, G ; QUEROL PAÑOL, JESSICA; Cosín, M ; Verde, G ; Cigliano, R A ; Sanseverino, W ; Segura-Bayona, S ; Iturbide, A ; Andreu, D ; NUCIFORO, PAOLO GIOVANNI; Bernado-Morales, C ; RODILLA BENITO, VERONICA; ARRIBAS LOPEZ, JOAQUIN VICENTE; Yelamos, J ; de Herreros, A Garcia ; Stracker, T H ; PEIRO SALES, SANDRA. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. 2020 January. 10.1038/s41388-019-0969-1
  • NUCIFORO, PAOLO GIOVANNI; Townend, J. ; SAURA MANICH, CRISTINA; de Azumbaja, E. ; Hilbers, F. ; Manukyants, A. ; Werutsky, G. ; Bliss, J. ; Moebus, V. ; Colleoni, M. ; Aspitia, A.M. ; Di Cosimo, S. ; Van dooren, V. ; Kroep, J. ; Ferro, A. ; Cameron, D. ; Gelber, R. ; Piccart-Gebhart, M. ; Huober, J. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. EUROPEAN JOURNAL OF CANCER. 2020 January. 10.1016/S0959-8049(20)30560-8
  • Amgad, Mohamed ; Stovgaard, Elisabeth Specht ; Balslev, Eva ; Thagaard, Jeppe ; Chen, Weijie ; Dudgeon, Sarah ; Sharma, Ashish ; Kerner, Jennifer K ; Denkert, Carsten ; Yuan, Yinyin ; AbdulJabbar, Khalid ; Wienert, Stephan ; Savas, Peter ; Voorwerk, Leonie ; Beck, Andrew H ; Madabhushi, Anant ; Hartman, Johan ; Sebastian, Manu M ; Horlings, Hugo M ; Hudecek, Jan ; Ciompi, Francesco ; Moore, David A ; Singh, Rajendra ; Roblin, Elvire ; Balancin, Marcelo Luiz ; Mathieu, Marie-Christine ; Lennerz, Jochen K ; Kirtani, Pawan ; Chen, I-Chun ; Braybrooke, Jeremy P ; Pruneri, Giancarlo ; Demaria, Sandra ; Adams, Sylvia ; Schnitt, Stuart J ; Lakhani, Sunil R ; Rojo, Federico ; Comerma, Laura ; Badve, Sunil S ; Khojasteh, Mehrnoush ; Symmans, W Fraser ; Sotiriou, Christos ; Gonzalez-Ericsson, Paula ; Pogue-Geile, Katherine L ; Kim, Rim S ; Rimm, David L ; Viale, Giuseppe ; Hewitt, Stephen M ; Bartlett, John M S ; Penault-Llorca, Frédérique ; Goel, Shom ; Lien, Huang-Chun ; Loibl, Sibylle ; Kos, Zuzana ; Loi, Sherene ; Hanna, Matthew G ; Michiels, Stefan ; Kok, Marleen ; Nielsen, Torsten O ; Lazar, Alexander J ; Bago-Horvath, Zsuzsanna ; Kooreman, Loes F S ; van der Laak, Jeroen A W M ; Saltz, Joel ; Gallas, Brandon D ; Kurkure, Uday ; Barnes, Michael ; Salgado, Roberto ; Hyytiäinen, Aini ; International Immuno-Oncology Biomarker Working Group ; Hida, Akira I ; Thompson, Alastair ; Lefevre, Alex ; Gown, Allen ; Lo, Amy ; Sapino, Anna ; Moreira, Andre ; Richardson, Andrea ; Vingiani, Andrea ; Bellizzi, Andrew M ; Tutt, Andrew ; Guerrero-Zotano, Angel ; Grigoriadis, Anita ; Ehinger, Anna ; Garrido-Castro, Anna C ; Vincent-Salomon, Anne ; Laenkholm, Anne-Vibeke ; Cimino-Mathews, Ashley ; Srinivasan, Ashok ; Acs, Balazs ; Singh, Baljit ; Calhoun, Benjamin ; Haibe-Kans, Benjamin ; Solomon, Benjamin ; Thapa, Bibhusal ; Nelson, Brad H ; Castaneda, Carlos ; Ballesteroes-Merino, Carmen ; Criscitiello, Carmen ; Boeckx, Carolien ; Colpaert, Cecile ; Quinn, Cecily ; Chennubhotla, Chakra S ; Swanton, Charles ; Solinas, Cinzia ; Hiley, Crispin ; Drubay, Damien ; Bethmann, Daniel ; Dillon, Deborah A ; Larsimont, Denis ; Sabanathan, Dhanusha ; Peeters, Dieter ; Zardavas, Dimitrios ; Höflmayer, Doris ; Johnson, Douglas B ; Thompson, E Aubrey ; Brogi, Edi ; Perez, Edith ; ElGabry, Ehab A ; Blackley, Elizabeth F ; Reisenbichler, Emily ; Bellolio, Enrique ; Chmielik, Ewa ; Gaire, Fabien ; Andre, Fabrice ; Lu, Fang-I ; Azmoudeh-Ardalan, Farid ; Gruosso, Forbius Tina ; Peale, Franklin ; Hirsch, Fred R ; Klaushen, Frederick ; Acosta-Haab, Gabriela ; Farshid, Gelareh ; van den Eynden, Gert ; Curigliano, Giuseppe ; Floris, Giuseppe ; Broeckx, Glenn ; Koeppen, Harmut ; Haynes, Harry R ; McArthur, Heather ; Joensuu, Heikki ; Olofsson, Helena ; Cree, Ian ; Nederlof, Iris ; Frahm, Isabel ; Brcic, Iva ; Chan, Jack ; Hall, Jacqueline A ; Ziai, James ; Brock, Jane ; Wesseling, Jelle ; Giltnane, Jennifer ; Lemonnier, Jerome ; Zha, Jiping ; M Ribeiro, Joana ; Carter, Jodi M ; Hainfellner, Johannes ; Quesne, John Le ; Juco, Jonathan W ; Reis-Filho, Jorge ; van den Berg, Jose ; Sanchez, Joselyn ; Sparano, Joseph ; Cucherousset, Joël ; Araya, Juan Carlos ; Adam, Julien ; Balko, Justin M ; Saeger, Kai ; Siziopikou, Kalliopi ; Willard-Gallo, Karen ; Sikorska, Karolina ; Weber, Karsten ; Steele, Keith E ; Emancipator, Kenneth ; El Bairi, Khalid ; Blenman, Kim R M ; Allison, Kimberly H ; van de Vijver, Koen K ; Korski, Konstanty ; Pusztai, Lajos ; Buisseret, Laurence ; Shi, Leming ; Shi-Wei, Liu ; Molinero, Luciana ; Estrada, M Valeria ; van Seijen, Maartje ; Lacroix-Triki, Magali ; Cheang, Maggie C U ; Bakir, Maise Al ; van de Vijver, Marc ; Dieci, Maria Vittoria ; Rebelatto, Marlon C ; Piccart, Martine ; Goetz, Matthew P ; Preusser, Matthias ; Sanders, Melinda E ; Regan, Meredith M ; Christie, Michael ; Misialek, Michael ; Ignatiadis, Michail ; de Maaker, Michiel ; van Bockstal, Mieke ; Castillo, Miluska ; Harbeck, Nadia ; Tung, Nadine ; Laudus, Nele ; Sirtaine, Nicolas ; Burchardi, Nicole ; Ternes, Nils ; Radosevic-Robin, Nina ; Gluz, Oleg ; Grimm, Oliver ; Nuciforo, Paolo ; NUCIFORO, PAOLO GIOVANNI; Jelinic, Petar ; Watson, Peter H ; Francis, Prudence A ; Russell, Prudence A ; Pierce, Robert H ; Hills, Robert ; Leon-Ferre, Roberto ; de Wind, Roland ; Shui, Ruohong ; Declercq, Sabine ; Leung, Sam ; Tabbarah, Sami ; Souza, Sandra C ; O’Toole, Sandra ; Swain, Sandra ; Willis, Scooter ; Ely, Scott ; Kim, Seong- Rim ; Bedri, Shahinaz ; Irshad, Sheeba ; Liu, Shi-Wei ; Hendry, Shona ; Bianchi, Simonetta ; Bragança, Sofia ; Paik, Soonmyung ; Fox, Stephen B ; Luen, Stephen J ; Naber, Stephen ; Luz, Sua ; Fineberg, Susan ; Soler, Teresa ; Gevaert, Thomas ; d’Alfons, Timothy ; John, Tom ; Sugie, Tomohagu ; Bossuyt, Veerle ; Manem, Venkata ; Cámaea, Vincente Peg ; Tong, Weida ; Yang, Wentao ; Tran, William T ; Wang, Yihong ; Allory, Yves ; Husain, Zaheed ; Husain Z. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.  NPJ breast cancer. 2020 January. 10.1038/s41523-020-0154-2
  • Brasó-Maristany, Fara ; Griguolo, Gaia ; Pascual, Tomás ; Paré, Laia ; NUCIFORO, PAOLO GIOVANNI; Llombart-Cussac, Antonio ; Bermejo, Begoña ; ANTUNES DE MELO E OLIVEIRA, MAFALDA; Morales, Serafín ; Martínez, Noelia ; VIDAL LOSADA, Mª JESUS; Adamo, Barbara ; Martínez, Olga ; Pernas, Sonia ; López, Rafael ; Muñoz, Montserrat ; Chic, Núria ; Galván, Patricia ; Garau, Isabel ; Manso, Luis ; Alarcón, Jesús ; Martínez, Eduardo ; Gregorio, Sara ; Gomis, Roger R ; Villagrasa, Patricia ; CORTES CASTAN, JAVIER; Ciruelos, Eva ; Prat, Aleix. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. NATURE COMMUNICATIONS. 2020 January. 10.1038/s41467-019-14111-3
  • Di Cosimo, Serena ; Appierto, Valentina ; Pizzamiglio, Sara ; Silvestri, Marco ; Baselga, José ; Piccart, Martine ; Huober, Jens ; Izquierdo, Miguel ; de la Pena, Lorena ; Hilbers, Florentine S ; de Azambuja, Evandro ; Untch, Michael ; Pusztai, Lajos ; Pritchard, Kathleen ; NUCIFORO, PAOLO GIOVANNI; Vincent-Salomon, Anne ; Symmans, Fraser ; Apolone, Giovanni ; de Braud, Filippo G ; Iorio, Marilena V ; Verderio, Paolo ; Daidone, Maria Grazia. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2020 February. 10.3390/ijms21041386
  • De Angelis, Carmine; Nagi, Chandandeep ; Hoyt, Cliff C ; Liu, Linying ; Roman, Kristin ; Wang, Chichung ; Zheng, Yi ; Veeraraghavan, Jamunarani ; Sethunath, Vidyalakshmi ; NUCIFORO, PAOLO GIOVANNI; Wang, Tao ; Tsimelzon, Anna ; Mao, Sufeng ; Hilsenbeck, Susan G ; Trivedi, Meghana V ; Cataldo, Maria Letizia ; Pavlick, Anne ; Wolff, Antonio C ; Weigelt, Britta ; Reis-Filho, Jorge S ; Prat, Aleix ; Gutierrez, Carolina ; Osborne, Charles Kent ; Rimawi, Mothaffar F ; Schiff, Rachel. Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without CLINICAL CANCER RESEARCH. 2020 February. 10.1158/1078-0432.CCR-19-1402
  • CAPDEVILA CASTILLON, JAUME; ARQUES CASAMITJANA, ORIOL; Hernandez Mora, Jose Ramon ; MATITO ARIZA, JUDIT; CARATU, GINEVRA; MANCUSO, FRANCESCO MATTIA; Landolfi, Stefania ; Barriuso, Jorge ; Jimenez-Fonseca, Paula ; Lopez Lopez, Carlos ; Garcia-Carbonero, Rocio ; Hernando, Jorge ; MATOS GARCIA, IGNACIO; NUCIFORO, PAOLO GIOVANNI; Hernández-Losa, Javier ; Esteller, Manel ; Martínez-Cardús, Anna ; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; GARCIA PALMER, HECTOR. Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. CLINICAL CANCER RESEARCH. 2020 February. 10.1158/1078-0432.CCR-19-1266
  • GARCIA VALVERDE, LUIS ALFONSO; Rosell, Jordi; Serna, Garazi ; VALVERDE MORALES, CLAUDIA M; CARLES GALCERAN, JOAN; NUCIFORO, PAOLO GIOVANNI; Fletcher, Jonathan A ; ARRIBAS LOPEZ, JOAQUIN VICENTE; Politz, Oliver ; SERRANO GARCIA, CESAR. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. MOLECULAR CANCER THERAPEUTICS. 2020 June. 1158/1535-7163.MCT-19-1069
  • Tamborero, David ; DIENSTMANN, RODRIGO; Rachid, Maan Haj ; Boekel, Jorrit ; Baird, Richard ; BRAÑA GARCIA, IRENE; De Petris, Luigi ; Yachnin, Jeffrey ; Massard, Christophe ; Opdam, Frans L ; Schlenk, Richard ; Vernieri, Claudio ; GARRALDA CABANAS, ELENA; Masucci, Michele ; VILLALOBOS ALBERU, XENIA; CHAVARRIA MIRAS, ELENA; Cancer Core Europe consortium ; Calvo, Fabien ; Fröhling, Stefan ; Eggermont, Alexander ; Apolone, Giovanni ; Voest, Emile E ; Caldas, Carlos ; TABERNERO CATURLA, JOSEP; Ernberg, Ingemar ; RODON AHNERT, JORDI; Lehtiö, Janne ; Anand, Shubha ; AZARO, ANALIA BEATRIZ; Baars, Danny ; Bajalica-Lagercrantz, Svetlana ; BALMAÑA GELPI, JUDITH; Bergh, Jonas ; Bierkens, Mariska ; Blomqvist, Lennart ; Doherty, Gary J ; Forest, Arnauld ; Fornerone, Valentina ; Funingana, Ionut Gabriel ; Gabaldi, Paola ; Hartman, Johan ; Horak, Peter ; Karlsson, Claes ; Kasanicki, Mary ; Kreutzfeldt, Simon ; Lewensohn, Rolf ; Lindberg, Johan ; Lopez, Carlos ; Lundqvist, Andreas ; Martin-Romano, Patricia ; Martin, Jose-Ezequiel ; Meijer, Gerrit ; Muñoz, Susana ; Camus, Maud Ngo ; Nicotra, Claudio ; NUCIFORO, PAOLO GIOVANNI; Oberrauch, Petra ; Östling, Päivi ; PIRIS GIMENEZ, ALEJANDRO; Provenzano, Elena ; Rouleau, Etienne ; Rowell, John ; SAAVEDRA SANTAGADEA, OMAR; Valdivia, Ignacio Sánchez ; Scoazec, Giovanni ; Seamon, Kenneth ; Tischkowitz, Marc ; van der Kolk, Lizet ; van der Noll, Ruud ; Vis, Daniel ; VIVANCOS PRELLEZO, ANA; von Gertten, Christina ; Wennborg, Anders ; Wessels, Lodewyk ; Wirta, Valtteri ; Wolfart, Julia. Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. NATURE MEDICINE. 2020 July. 10.1038/s41591-020-0969-2
  • GRIS OLIVER, ALBERT; PALAFOX SANCHEZ, MARTA; MONTSERRAT VICENTE, LAIA; Brasó-Maristany, Fara ; Òdena, Andreu ; SANCHEZ GUIXE, MONICA; IBRAHIM, YASIR HUSSEIN; VILLACAMPA JAVIERRE, GUILLERMO; GRUESO GRAGERA, JUDIT; Parés, Mireia ; GUZMAN, MARTA; RODRIGUEZ FERREIRO, OLGA; Bruna, Alejandra ; Hirst, Caroline S ; Barnicle, Alan ; de Bruin, Elza C ; Reddy, Avinash ; Schiavon, Gaia ; ARRIBAS LOPEZ, JOAQUIN VICENTE; Mills, Gordon B ; Caldas, Carlos ; Dienstman, Rodrigo ; PRAT APARICIO, ALEIX; NUCIFORO, PAOLO GIOVANNI; Razavi, Pedram ; SCALTRITI, MAURIZIO; Turner, Nicholas C ; SAURA MANICH, CRISTINA; Davies, Barry R ; Oliveira, Mafalda ; SERRA ELIZALDE, VIOLETA. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. CLINICAL CANCER RESEARCH. 1158/1078-0432.CCR-19-3324
  • Lupo, Barbara ; Sassi, Francesco ; Pinnelli, Marika ; Galimi, Francesco ; Zanella, Eugenia R ; Vurchio, Valentina ; Migliardi, Giorgia ; Gagliardi, Paolo Armando ; Puliafito, Alberto ; Manganaro, Daria ; Luraghi, Paolo ; Kragh, Michael ; Pedersen, Mikkel W ; Horak, Ivan D ; Boccaccio, Carla ; Medico, Enzo ; Primo, Luca ; Nichol, Daniel ; Spiteri, Inmaculada ; Heide, Timon ; Vatsiou, Alexandra ; Graham, Trevor A ; ELEZ FERNANDEZ, MARIA ELENA; ARGILES MARTINEZ, GUILLERMO; NUCIFORO, PAOLO GIOVANNI; Sottoriva, Andrea ; DIENSTMANN, RODRIGO; Pasini, Diego ; Grassi, Elena ; Isella, Claudio ; Bertotti, Andrea ; Trusolino, Livio. Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype. SCIENCE TRANSLATIONAL MEDICINE. 2020 August. 10.1126/scitranslmed.aax8313
  • Ciruelos, Eva M ; Villagrasa, Patricia ; Pascual, Tomás ; Oliveira, Mafalda ; Pernas, Sonia ; Paré, Laia ; ESCRIVA DE ROMANI MUÑOZ, SANTIAGO; Manso, Luis ; Adamo, Barbara ; Martínez de Dueñas, Eduardo ; CORTES CASTAN, JAVIER; Vázquez, Silvia ; Perelló, Antonia ; Garau, Isabel ; Melé, Mireia ; Martínez Jañez, Noelia ; Montaño, Alvaro ; Bermejo, Begoña ; Morales, Serafín ; Echarri, Mª Jose ; Vega, Estela ; González-Farré, Blanca ; Martínez, Débora ; GALVAN JURADO, PATRICIA; Canes, Jordi ; NUCIFORO, PAOLO GIOVANNI; Gonzàlez Farré, Xavier ; Prat, Aleix. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. CLINICAL CANCER RESEARCH. 2020 November. 1158/1078-0432.CCR-20-0844
  • Zunder, Stéphanie M ; PEREZ LOPEZ, RAQUEL; de Kok, Bente M ; Raciti, Maria Vittoria ; van Pelt, Gabi W ; DIENSTMANN, RODRIGO; Garcia-Ruiz, Alonso ; Meijer, C Arnoud ; Gelderblom, Hans ; Tollenaar, Rob A ; NUCIFORO, PAOLO GIOVANNI; Wasser, Martin N ; Mesker, Wilma E. Correlation of the tumour-stroma ratio with diffusion weighted MRI in rectal cancer. EUROPEAN JOURNAL OF RADIOLOGY. 2020 December. 10.1016/j.ejrad.2020.109345
  • Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Serna G, Ruiz-Pace F, Cecchi F, Fasani R, Jimenez J, Thyparambil S, Landolfi S, Elez E, Vivancos A, Hembrough T, Tabernero J, Dienstmann R, Nuciforo P. Sci Rep. 2019 Sep 19;9(1):13568.
  • Early evolutionary divergence between papillary and anaplastic thyroid cancers. Capdevila J, Mayor R, Mancuso FM, Iglesias C, Caratú G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez CV, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Ann Oncol. 2019 Nov 1;30(11):1843.
  • Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Mol Oncol. 2019 Sep;13(9):1827-1835.
  • Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. Vivancos A, Aranda E, Benavides M, Élez E, Gómez-España MA, Toledano M, Alvarez M, Parrado MRC, García-Barberán V, Diaz-Rubio E. Sci Rep. 2019 Jun 20;9(1):8976.
  • Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer. Rodriguez-Freixinos V, Ruiz-Pace F, Fariñas-Madrid L, Garrido-Castro AC, Villacampa G, Nuciforo P, Vivancos A, Dienstmann R, Oaknin A. ESMO Open. 2019 Mar 8;4(2):e000444.
  • Vivancos A, Élez E, Salazar R. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime? Ann Oncol.29: 532-534.
  • Capdevila J, Mayor R; Mancuso FF, Iglesias C; Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez C, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol.29: 1454-1460.
  • Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. J Natl Cancer Inst. 110: 914-917.
  • Puig I, Tenbaum SP, Chicote I, Arqués O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratù G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo AG, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J, Palmer HG. TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. J Clin Invest. 128: 3887-3905.
  • Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN; Kristel P, de Bustos L, Guzman M, Rodriguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O; O’Connor MJ, Balmaña J, Serra V. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 29: 1203-1210.
  • Martínez-Ricarte F, Mayor R, Martínez-Sáez E, Rubio-Pérez C, Pineda E, Cordero E, Cicuéndez M, Poca MA, Lopez-Bigas N, Ramón Y Cajal S, Vieito M, Carles J, Tabernero J, Vivancos A, Gallego S, Graus F, Sahuquillo J, Seoane J. Molecular Diagnosis of Diffuse Gliomas through Sequencing of Cell-Free Circulating Tumor DNA from Cerebrospinal Fluid. Clin Cancer Res. 24: 2812-2819.
  • Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel J M, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer H G, Vivancos A. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2017 Oct 1;28(10):2451-2457.
  • García-Foncillas J, Alba E, Aranda E, Díaz-Rubio E, López-López R, Tabernero J, Vivancos A. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol. 2017 Dec 1;28(12):2943-2949.
  • Dienstmann R, Elez E, Argiles G, Matos I, Sanz-Garcia E, Ortiz C, Macarulla T, Capdevila J, Alsina M, Sauri T, Verdaguer H, Vilaro M, Ruiz-Pace F, Viaplana C, Garcia A, Landolfi S, Palmer HG, Nuciforo P, Rodon J, Vivancos A, Tabernero J. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights. Mol Oncol. 2017 Sep;11(9):1263-1272.
  • Grasselli J, Elez E, Caratù G, Matito J, Santos C, Macarulla T, Vidal J, Garcia M, Viéitez JM, Paéz D, Falcó E, Lopez Lopez C, Aranda E, Jones F, Sikri V, Nuciforo P, Fasani R, Tabernero J, Montagut C, Azuara D, Dienstmann R, Salazar R, Vivancos A. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017 Jun 1;28(6):1294-1301.
  • Pérez-Alea M, Vivancos A, Caratú G, Matito J, Ferrer B, Hernandez-Losa J, Cortés J, Muñoz E, Garcia-Patos V, Recio JA. Genetic profile of GNAQ-mutated blue melanocytic neoplasms reveals mutations in genes linked to genomic instability and the PI3K pathway. Oncotarget. 2016 May 10;7(19):28086-95. doi: 10.18632/oncotarget.8578.
  • Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081.
  • Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.
  • Alves-Rodrigues I, Ferreira PG, Moldón A, Vivancos AP, Hidalgo E, Guigó R, Ayté J. Spatiotemporal Control of Forkhead Binding to DNA Regulates the Meiotic Gene Expression Program. Cell Rep. 2016 Feb 2;14(4):885-95. doi: 10.1016/j.celrep.2015.12.074.
  • Vivancos A, Caratú G, Matito J, Muñoz E, Ferrer B, Hernández-Losa J, Bodet D, Pérez-Alea M, Cortés J, Garcia-Patos V, Recio JA. Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP1 and TP53 mutations. Pigment Cell Melanoma Res. 2016 Mar;29(2):247-53. doi: 10.1111/pcmr.12452.
  • Yus E, Güell M, Vivancos AP, Chen WH, Lluch-Senar M, Delgado J, Gavin AC, Bork P, Serrano L. Transcription start site associated RNAs in bacteria. Mol. Syst. Biol. 2012; 8: 585
  • Esteve-Codina A, Kofler R, Himmelbauer H, Ferretti L, Vivancos AP, Groenen MA, Folch JM, Rodríguez MC, Pérez-Enciso M. Partial short-read sequencing of a highly inbred Iberian pig and genomics inference thereof. Heredity (Edinb) 2011 Sep; 107(3): 256-64
  • Zuin A, Carmona M, Morales-Ivorra I, Gabrielli N, Vivancos AP, Ayté J, Hidalgo E. Lifespan extension by calorie restriction relies on the Sty1 MAP kinase stress pathway. EMBO J. 2010 Mar; 29(5): 981-91
  • Vivancos AP, Castillo EA, Biteau B, Nicot C, Ayté J, Toledano MB, Hidalgo E. A cysteine-sulfinic acid in peroxiredoxin regulates H2O2-sensing by the antioxidant Pap1 pathway. Proc. Natl. Acad. Sci. U.S.A. 2005 Jun; 102(25): 8875-80
  • Vivancos AP, Castillo EA, Jones N, Ayté J, Hidalgo E. Activation of the redox sensor Pap1 by hydrogen peroxide requires modulation of the intracellular oxidant concentration. Mol. Microbiol. 2004 Jun; 52(5): 1427-35
  • Castillo EA, Vivancos AP, Jones N, Ayté J, Hidalgo E. Schizosaccharomyces pombe cells lacking the Ran-binding protein Hba1 show a multidrug resistance phenotype due to constitutive nuclear accumulation of Pap1. J. Biol. Chem. 2003 Oct; 278(42): 40565-72
  • FUSOMAP: Development of microbiota-based diagnostic and prognostic models by mapping intratumoral Fusobacterium and associated gut microbiota in early-stage colorectal cancer – Mutua Madrileña and ISCIII.
  • Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based patient stratification solutions – COLOSSUS, H2020.
  • Opportunity: To Investigate the Microbiome’s Impact on Science and Treatment In Colorectal Cancer – OPTIMISTICC, Grand Challenge, Cancer Research UK.
  • Microbiota composition as risk predictor in cancer patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – La Marató TV3, 2021.
  • Development and validation of Fusobacterium and its associated microbiota as risk stratification biomarker after SoC treatment in locally advanced rectal cancer. Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR). 1/02/2024-31/07/2025. PI: Paolo Nuciforo.

Noticias Relacionadas

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.